| # | Company | Location | Employees | Total Funding | Last Round | Last Funded |
|---|---|---|---|---|---|---|
| 1 |
Alvotech
Alvotech is a biotechnology company that specializes in making biosimilars to cr…
|
Reykjav├¡k | — | $2.0B | Post Ipo Debt | 2025-12-31 |
| 2 |
Chai Discovery
Chai Discovery develops artificial intelligence models that predict and reprogra…
|
San Francisco | — | $231.0M | Series B | 2025-12-15 |
| 3 |
Nuclera
Nuclera offers a protein prototyping system to accelerate drug discovery by maki…
|
Cambridge | — | $157.8M | Series C | 2026-01-13 |
| 4 |
Juvena Therapeutics
Juvena Therapeutics develops tissue-restorative biologics to address chronic mus…
|
Palo Alto | 11 - 50 | $113.2M | Series B | 2026-01-12 |
| 5 |
Apprentice.io
The industry's first agentic AI manufacturing platform built for a world beyond …
|
Jersey City | 101 - 250 | $207.0M | Series C | 2023-03-20 |
| 6 |
Parabilis Medicines
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specialize…
|
Cambridge | 101 - 250 | $835.3M | Series F | 2026-01-08 |
| 7 |
Alumis
Alumis is a precision medicine company focused on the discovery, development and…
|
San Francisco | 101 - 250 | $917.2M | Post Ipo Equity | 2026-01-07 |
| 8 |
Sanofi
Sanofi is a global biopharma company focused on prescription drugs, vaccines, an…
|
Paris | c 10001 max | $7.0B | Post Ipo Debt | 2025-10-28 |
| 9 |
BioAge Labs
BioAge Labs is a clinical-stage biotechnology company that develops therapeutics…
|
Richmond | 51 - 100 | $408.9M | Post Ipo Equity | 2026-01-21 |
| 10 |
Diagonal Therapeutics
Diagonal Therapeutics is a biotechnology startup that develops targeted therapie…
|
Watertown | 11 - 50 | $253.0M | Series B | 2026-01-08 |
| 11 |
Aktis Oncology
Aktis Oncology is a biotechnology company that designs and develops novel class …
|
Boston | 51 - 100 | $331.0M | Series B | 2024-09-30 |
| 12 |
Ukko
Ukko is a biotechnology company focused on developing immunotherapies for the tr…
|
Palo Alto | 11 - 50 | $92.7M | Series C | 2026-01-08 |
| 13 |
Caris Life Sciences
Caris Life Sciences develops molecular profiling and AI-driven technologies to s…
|
Irving | 1K - 5K | $1.9B | Private Equity | 2025-04-07 |
| 14 |
Lila Sciences
Lila Sciences creates a scientific superintelligence platform and autonomous lab…
|
Cambridge | 101 - 250 | $550.7M | Grant | 2026-01-20 |
| 15 |
Precede Biosciences
Precede Biosciences is a biotechnology company that provides a blood-based appro…
|
Boston | 11 - 50 | $140.5M | Series B | 2026-01-12 |
| 16 |
Myome
Myome helps identify genes that cause disease and act based on leading science.
|
Palo Alto | 11 - 50 | $23.0M | Series Unknown | 2025-12-11 |
| 17 |
Parse Biosciences
Parse Biosciences is a biotechnology startup company that develops single-cell s…
|
Seattle | 101 - 250 | $100.0M | Series C | 2023-12-14 |
| 18 |
Isomorphic Labs
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
|
London | 101 - 250 | $601.7M | Series A | 2025-03-31 |
| 19 |
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company pioneering Gene Writing™ to driv…
|
Cambridge | 251 - 500 | $773.1M | Grant | 2026-03-23 |
| 20 |
Beacon Therapeutics
Beacon Therapeutics is a biotechnology company that develops treatments to prese…
|
Alachua | 101 - 250 | $365.1M | Series C | 2026-01-08 |
| 21 |
Kyverna Therapeutics
Kyverna Therapeutics is pioneering a new class of therapies and cures for seriou…
|
Berkeley | 101 - 250 | $295.0M | Post Ipo Equity | 2025-12-17 |
| 22 |
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology o…
|
San Diego | 101 - 250 | $854.0M | Post Ipo Equity | 2026-01-21 |
| 23 |
Bactolife
Bactolife is a biotechnology company that develops biological solutions to suppo…
|
Lyngby | 11 - 50 | $81.5M | Series B | 2026-01-06 |
| 24 |
Cellares
Cellares is an Integrated Development and Manufacturing Organization dedicated t…
|
South San Francisco | 101 - 250 | $612.0M | Series C | 2023-08-23 |
| 25 |
Proxima
Proxima Bio develops programmable medicines that modulate protein interactions t…
|
New York | 11 - 50 | $86.3M | Seed | 2026-01-13 |
| 26 |
Think Bioscience
Think Bioscience is reimagining synthetic biology by guiding the design and asse…
|
Boulder | 11 - 50 | $78.3M | Series A | 2026-01-20 |
| 27 |
Enable Injections
Enable Injections develops and manufactures wearable drug delivery systems cente…
|
Cincinnati | 101 - 250 | $352.0M | Corporate Round | 2026-01-06 |
| 28 |
InduPro
InduPro deevlops proximity-based protein therapeutics that modulate cell-surface…
|
Seattle | 11 - 50 | $85.0M | Corporate Round | 2026-01-07 |
| 29 |
Colossal Biosciences
Colossal Biosciences is a biotechnology and genetic engineering company that use…
|
Austin | 101 - 250 | $628.1M | Series C | 2026-02-03 |
| 30 |
Truvian Sciences
Truvian Sciences develops an automated benchtop system to provide lab-accurate b…
|
San Diego | 101 - 250 | $208.1M | Series D | 2024-07-17 |
| 31 |
Addition Therapeutics
Addition Therapeutics develops RNA-only therapeutics using PRINT technology for …
|
South San Francisco | 11 - 50 | $100.0M | Series A | 2025-12-17 |
| 32 |
Insitro
Insitro is a drug discovery and development startup that utilizes machine learni…
|
South San Francisco | 251 - 500 | $643.0M | Series C | 2021-03-15 |
| 33 |
Cartography Biosciences
Cartography is an oncology company that develops cancer immunotherapies that tar…
|
South San Francisco | 11 - 50 | $124.0M | Series B | 2025-10-02 |
| 34 |
Replicate Bioscience
Replicate Bioscience develops self-replicating RNA therapeutics and vaccines del…
|
San Diego | 11 - 50 | $53.0M | Grant | 2026-01-08 |
| 35 |
Element Biosciences
Element Biosciences is a life science company that focuses on developing innovat…
|
San Diego | 251 - 500 | $678.0M | Series D | 2024-07-11 |
| 36 |
Scribe Therapeutics
Scribe Therapeutics is a biotech company that develops and engineers new therape…
|
Alameda | 51 - 100 | $120.0M | Convertible Note | 2023-05-16 |
| 37 |
Ultima Genomics
Ultima Genomics is a developer of a low-cost sequencing platform.
|
Newark | 251 - 500 | $600.0M | Series Unknown | 2022-05-31 |
| 38 |
Vizgen
Vizgen provides spatial multi-omics platforms enabling researchers to reveal cel…
|
Cambridge | 101 - 250 | $187.7M | Series E | 2026-01-08 |
| 39 |
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolu…
|
Hayward | 251 - 500 | $1.1B | Series D | 2025-02-26 |
| 40 |
Engitix
Engitix is operates as a tissue engineering company.
|
London | 51 - 100 | $85.4M | Series A | 2026-01-08 |
| 41 |
Excelsior Sciences
Excelsior Sciences applies AI and automated chemistry to simplify small-molecule…
|
New York | 11 - 50 | $95.0M | Grant | 2025-12-03 |
| 42 |
Noetik
Noetik is an AI-native biotechnology company that applies machine learning to la…
|
South San Francisco | 11 - 50 | $55.0M | Grant | 2024-09-12 |
| 43 |
Alloy Therapeutics
Alloy Therapeutics is a biotech company that makes medicine by democratizing acc…
|
Waltham | 11 - 50 | $128.2M | Series E | 2026-04-15 |
| 44 |
Tubulis
Tubulis generates antibody-drug conjugates with unique properties for solid tumo…
|
Munich | 51 - 100 | $616.9M | Series C | 2025-10-15 |
| 45 |
Atavistik Bio
Atavistik Bio is a biotechnology company that develops precision allosteric smal…
|
Cambridge | 11 - 50 | $260.0M | Series B | 2026-03-05 |
| 46 |
SOPHiA GENETICS
SOPHiA GENETICS is a biotechnology firm that aims to support healthcare professi…
|
Boston | 251 - 500 | $265.2M | Post Ipo Debt | 2024-05-02 |
| 47 |
Alida Biosciences
Alida Biosciences develops advanced RNA analysis platforms and software for prec…
|
San Diego | 11 - 50 | $17.0M | Grant | 2025-11-04 |
| 48 |
Orbital Therapeutics
Orbital Therapeutics is a biotechnology company that develops RNA-based medicine…
|
Cambridge | 11 - 50 | $270.0M | Series A | 2023-04-26 |
| 49 |
Latent Labs
Latent Labs is a biology programmable to transform health and sustainability for…
|
London | 11 - 50 | $50.0M | Series A | 2025-02-13 |
| 50 |
Arthrosi Therapeutics
Arthrosi Therapeutics develops pharmaceutical treatments through clinical resear…
|
San Diego | 11 - 50 | $277.4M | Series E | 2025-06-23 |